This review summarizes recent advances in our understanding of the regulation, activation and mechanisms of Wnt/betacatenin signalling in the pathogenesis of kidney fibrosis, and discusses the therapeutic potential of targeting this pathway for the treatment of chronic kidney disease.
ABSTRACT:
Wnt/β-catenin is an evolutionarily conserved, developmental signalling pathway that regulates embryogenesis, injury repair and pathogenesis of human diseases. Dysregulated activation of Wnt/β-catenin is associated with the development and progression of renal fibrotic lesions after injury. Wnt are induced and β-catenin is activated in various models of experimental chronic kidney disease (CKD) and in human nephropathies. Recent findings indicate that pro(renin) receptor is an amplifier of Wnt/β-catenin by acting as a downstream target and an obligatory component for its signal transduction. Genetic blockade of Wnt secretion in a cell type-specific manner uncovers renal tubular epithelium as the major source of Wnt ligands in CKD. Wnt/β-catenin controls the expression of a wide variety of downstream mediators implicated in kidney fibrosis, such as fibronectin, Snail1, matrix metalloproteinase-7, hepatocyte growth factor and various components of the renin-angiotensin system. Targeted inhibition of Wnt/β-catenin is able to ameliorate kidney fibrotic lesions in pre-clinical settings. In this review, we summarize recent advances in our understanding of the regulation, signal transduction, role and mechanisms of Wnt/β-catenin signalling in the pathogenesis of kidney fibrosis. We also discuss the therapeutic potential of targeting this pathway for the treatment of fibrotic CKD.
Kidney fibrosis, characterized by excessive extracellular matrix (ECM) deposition leading to scar formation in renal parenchyma, is widely considered as the final common consequence of a variety of chronic kidney disease (CKD). 1, 2 Kidney injury often initiates from the tubular epithelium, which subsequently stimulates the activation of interstitial fibroblasts, leading to over-production and deposition of the ECM components. 3 In this context, a key question in the field is how the injured tubules trigger interstitial fibroblast activation. In the past several years, numerous hypotheses have been postulated, such as partial epithelial-to-mesenchymal transition (EMT), cell cycle arrest, metabolic alterations and accelerated tubular cell senescence. [3] [4] [5] [6] Despite these distinct possibilities, one common and unifying sequel is the conversion of normal tubular cells to a secretory phenotype, characterized by active production and secretion of a range of profibrotic factors, such as transforming growth factor-β (TGF-β), Wnt and hedgehog ligands. [7] [8] [9] [10] Wnt/β-catenin is an evolutionarily conserved, developmental signalling pathway implicated in regulating an assortment of biological processes, such as cell fate determination, tissue homeostasis, organ development and pathogenesis of human diseases. [11] [12] [13] Although quiescent in normal adult kidneys, Wnt/β-catenin is re-activated in various models of kidney injury. Mounting evidence has established a crucial role of this signalling pathway in regulating different kidney responses after injurious insults. These studies have been highlighted in several recent comprehensive reviews. [14] [15] [16] In this article, we only summarize the latest advance in our understanding of Wnt/β-catenin in the pathogenesis of kidney fibrosis.
PRINCIPLE OF WNT/Β-CATENIN SIGNALLING
The Wnt family comprises of a group of secreted, lipidmodified signalling glycoproteins. In mammalian, there are at least 19 members of the Wnt family (for more details, see the Wnt homepage: www.stanford.edu/group/nusselab/cgibin/Wnt), which are critical to kidney development, 13 and defects in Wnt signalling may lead to various human diseases, including developmental abnormalities and cancers. 12 Once secreted from the producing cells, Wnt proteins transmit the signal across the cell membrane through interactions with the Frizzled (Fzd) family of receptors and their co-receptors, the low-density lipoprotein receptor-related protein-5 or -6 (LRP-5/6) of the target cells. This triggers the activation of Disheveled (Dsh/Dvl). At Dsh level, Wnt signalling can branch into canonic, β-catenin-dependent and non-canonic, β-catenin-independent pathways. In canonic pathway, Wnt engagement with Fzd and LRP-5/6 results in the phosphorylation of LRP-6 and inhibition of glycogen synthase kinase-3β (GSK-3β), ultimately leading to dephosphorylation of β-catenin. This cascade of events stabilizes and activates β-catenin, and stimulates its translocation to nuclei, where it binds to T-cell factor (TCF)/lymphoid enhancer-binding factor to promote the transcription of Wnt-targeted genes (Fig. 1) .
The non-canonic Wnt signalling has two major branches: the Wnt/planar cell polarity pathway, and the Wnt/Ca2+ pathway. In planar cell polarity pathway, Dsh transmits signal to the small guanosine-5'-triphosphate-binding proteins Rho and Rac, and mediates cytoskeletal organization and coordinates polarization of cells within the plane of epithelial sheets. In Wnt/Ca2+ pathway, the Fzd receptor also interfaces with a trimeric G-protein and results in the release of calcium from endoplasmic reticulum, which ultimately induces the nuclear factor of activated T-cells, and regulates cell fate and migration.
Regardless of the results, signalling through Wnt is tightly regulated in a multitude of ways. There are several antagonists of Wnt signalling, including soluble Fzd-related proteins (sFRP) and the family of Dickkopf (DKK) proteins. The sFRP can bind to Wnt and prevent their interaction with cell surface receptors Fzd, effectively antagonizing Wnt signalling. 17 DKK proteins are shown to disrupt Wnt binding to its co-receptors and therefore inhibit β-catenin activation. Klotho, an anti-aging protein and predominantly expressed in the tubular epithelium of normal kidneys, is also an endogenous Wnt antagonist. 18 Both full-length and secreted
Klotho can effectively bind to multiple Wnt, thereby negatively controlling Wnt action.
PRO(RENIN) RECEPTOR AS AN AMPLIFIER OF WNT/β-CATENIN
Recent studies unravel that pro(renin) receptor (PRR), a single-pass transmembrane protein also known as an accessory protein of vacuolar H + -ATPase (V-ATPase), 19, 20 functions as an amplifier of the canonic Wnt/β-catenin signalling. 21 PRR was originally identified as a membrane receptor that can bind both renin and its inactive precursor prorenin. 22 After binding to PRR, prorenin or renin changes its conformation and gains its catalytic activity of converting angiotensinogen to angiotensin I, 22,23 the rate-limiting step in the cascade of renin-angiotensin system (RAS) activation. In addition, binding of renin or prorenin to the PRR also directly triggers intracellular signal transduction, leading to activation of the extracellular signal-regulated kinase 1 and 2. 22, 24, 25 This action of the PRR induces the expression of profibrotic genes, such as TGF-β, fibronectin, collagen I and plasminogen activator inhibitor-1 (PAI-1), by a mechanism independent of RAS activation. We recently noted a novel ligand-independent pathway by which PRR promotes kidney injury, and demonstrated a reciprocal, complex interaction between PRR and Wnt/β-catenin signalling. 21 Wnt/β-catenin controls PRR gene expression in kidney tubular epithelial cells both in vitro and in vivo, suggesting that PRR is a downstream target of this signalling. In return, PRR acts as an essential component of the Wnt receptor complex and is obligatory for its signal transduction (Fig. 1) . Knockdown of PRR completely abolishes β-catenin activation and its downstream target gene expression after Wnt stimulation. Therefore, PRR induction and Wnt/β-catenin activation instigate a vicious, selfperpetuating cycle, which leads to the amplification of pathogenic Wnt/β-catenin signalling. These results are in line with earlier observations from model organisms, such as Xenopus and Drosophila, in which PRR was also shown to be a component of the Wnt receptors complex and regulates embryonic development through this signal pathway. 26, 27 These studies also explain why genetic deletion of PRR, unlike renin, is lethal even when restricted to specific cells, such as cardiomyocytes and glomerular podocytes. 28, 29 As an accessory subunit of the V-ATPase, PRR also plays a pivotal role in acidifying intracellular compartments and transporting protons across cell membranes. 30 We showed that inhibition of the V-ATPase activity abolishes Wntmediated β-catenin activation, 21 illustrating that proper intracellular acidification mediated by PRR/V-ATPase complex is indispensable for Wnt/β-catenin signalling. Whether V-ATPase activity is required for Wnt signalling in vivo awaits further investigation.
CELLULAR SOURCES OF WNT LIGANDS
Although relatively silent in normal adult kidneys, Wnt/β-catenin signalling is re-activated in a wide variety of fibrotic CKD. 16, 31 Earlier studies demonstrated that 16 out of the 19 Wnt ligands are induced in different levels at various time points after unilateral ureteral obstruction (UUO), suggesting robust activation of Wnt signalling in this model. 32 Along with Wnt up-regulation, β-catenin and its target genes are also dramatically induced, and their expression is closely correlated with renal β-catenin abundance. 32 In addition, delivery of exogenous Wnt antagonists, such as sFRP4, DKK1, Klotho and β-catenin inhibitor ICG-001 significantly reduces renal β-catenin accumulation and inhibits the expression of its target genes. Wnt antagonists also repress myofibroblast activation and ameliorate renal fibrosis in CKD models. 17, 18, 32, 33 As Wnt ligands are widely expressed in virtually all types of cells in the kidney, one unsolved question was the cellular source(s) of the Wnt ligands that play a predominant role in mediating fibrotic responses. Immunostaining for Wnt proteins in human kidney biopsies from CKD patients reveal that multiple Wnt ligands are induced predominantly in renal tubular epithelium, as well as in the cells of renal interstitium, which presumably include fibroblasts, pericytes, infiltrating inflammatory cells and vascular and lymphatic endothelial cells. 7 Because Wntless (Wls) protein, also known as Evenness interrupted and Sprinter, is a conserved multi-span transmembrane cargo receptor dedicated to the trafficking and secretion of all Wnt ligands, 34 genetic ablation of its gene in a cell type-specific fashion will block Wnt secretion from that particular type of cells. Using this approach, we recently generated conditional knockout mice in which Wls is selectively ablated in renal tubular epithelium. Selective blockade of Wnt secretion from tubular epithelium in mice effectively preserves tubular epithelial cell integrity, inhibits myofibroblast activation and inflammation, and ultimately ameliorates kidney fibrosis after obstructive injury. In contrast, conditional knockout of Wls gene in interstitial fibroblasts does not affect the severity of kidney injury and fibrosis after obstructive and unilateral ischemia/reperfusion injury. 7 Consistent with these results, another independent study demonstrated that proximal tubular induction of Wnt1 expression alone is efficient to cause interstitial myofibroblast activation and increase matrix protein production. 9 Taken together, these studies indicate that tubule-derived Wnts play a major role in destructing tubular cell integrity and promoting fibroblast activation and matrix production by both autocrine and paracrine fashion. Using similar strategy, we recently studied the relative contribution of Wnts from other cellular sources to kidney fibrogenesis. In this regards, we found that mice with macrophage-specific deletion of Wls are protected against renal fibrosis after injury, suggesting that macrophagederived Wnts also play a role in promoting fibroblast activation. However, deletion of Wls from lymphatic endothelial cells does not alter fibrotic lesions after obstructive injury (unpublished data). Therefore, Wnt from multiple cellular sources contribute to its extracellular pool in the injured tissue. Tubule-or macrophage-derived Wnt are of particular importance in triggering the loss of tubular cell integrity and activation of myofibroblast, leading to scar tissue formation.
RECRUITMENT OF WNT LIGANDS
Wnt are secreted proteins produced by a variety of injured cells, and presumably disseminated in the extracellular compartments. It remains ambiguous how Wnt gradient in the injured kidney is formed. It is conceivable that Wnt ligands may not be distributed evenly across renal parenchyma, but could be recruited and concentrated focally by some unrecognized mechanisms, because kidney fibrotic lesion typically initiates at certain focal sites. We recently postulated the concept of the fibrogenic niche, and proposed tenascin-C (TNC), an ECM glycoprotein, as an organizer of such a functional entity. 35 TNC expression is increased rapidly in fibrotic kidneys and predominantly localizes at the foci rich in fibroblasts in renal interstitium. 35 Further loss-or gain-offunction studies have confirmed the role of TNC in organizing a specialized microenvironment that facilitates fibroblast activation and proliferation both in vitro and in vivo. 35 Recent data demonstrate that TNC could bind to and interact with Wnt ligands. 36 Through its physical binding, TNC is able to recruit and concentrate Wnt ligands from the surrounding milieu and presents them to fibroblasts (Chen et al., Kidney Int. Accepted). As such, Wnt ligands are recruited to and enriched in the fibrogenic niche (Fig. 1) , setting up a favourable tissue microenvironment for fibroblast proliferation and matrix over-production.
TARGETS AND MECHANISM
Wnt/β-catenin elicits its biological activities by inducing the expression of its target genes. Over the last several years, numerous Wnt/β-catenin target genes that are highly relevant to kidney fibrosis are characterized, including fibronectin, fibroblast-specific protein 1, Snail1, matrix metalloproteinase-7 (MMP-7), PAI-1, RAS components and hepatocyte growth factor (HGF) (Fig. 1 ). Of these Wnt target genes, fibronectin is an ECM component, whereas fibroblast-specific protein 1 is a marker for fibroblasts and myofibroblasts. Snail1 is a key transcription factor that represses E-cadherin expression and induces inhibitor of differentiation 1 (Id1). This leads to the disruption of epithelial cell-cell adhesion, drives partial EMT. 37 PAI-1 is a secreted acute-phase glycoprotein that could inhibit both tissue-type and urokinase-type plasminogen activators. Wnt stimulation could induce PAI-1 expression in renal tubular cells, and disruption of the TCF/lymphoid enhancer-binding factor-binding site in its promoter region abolished this effect. Similarly, blockade of β-catenin signalling also inhibited PAI-1 induction. 38 Another downstream target of Wnt/β-catenin signalling is MMP-7, a secreted endopeptidase that degrades ECM and other substrates. 39 The molecular mechanism behind the pathogenic action of MMP-7 is most likely related to its ability to promote EMT by degrading E-cadherin. 40 Our previous studies showed the levels of renal and urinary MMP-7 correlate with Wnt/β-catenin activity. 39, 40 Furthermore, urinary MMP-7 levels correlates with kidney fibrosis in humans and knockout of MMP-7 ameliorates the fibrotic lesions and expression of matrix genes in UUO model. 40 Moreover, endogenous MMP-7 promotes kidney fibrosis by activating β-catenin through a mechanism independent of Wnts, demonstrating that MMP-7 is not only a biomarker for renal fibrosis but also a major pathogenic mediator in the evolution of fibrotic lesions. 40 It is well documented that RAS activation has deleterious effects on the kidney. 41, 42 Interestingly, recent studies have pointed out that multiple RAS genes including angiotensinogen, renin, angiotensin-converting enzyme and angiotensin II type I receptor are novel downstream targets of Wnt/β-catenin signalling in diseased kidney. 43 All RAS genes possess putative binding sites for TCF/β-catenin in their promoter regions, and Wnt/β-catenin induces the expression of multiple RAS genes in tubular epithelial cells. Furthermore, inhibition of Wnt/β-catenin represses RAS activation, ameliorates kidney fibrosis and also reduces renal inflammation and normalizes blood pressure in mouse model of CKD. 43 In this context, Wnt/β-catenin and RAS are intimately linked to constitute a pathologic axis that plays a crucial role in the pathogenesis of CKD. 41 Besides induction of its target genes, Wnt/β-catenin is also able to negatively regulate its downstream genes by inhibiting their expression. In this regards, we recently showed that Wnt/β-catenin represses HGF gene expression in renal interstitial fibroblast cells both in vivo and in vitro. 44 As HGF is a potent anti-fibrotic factor that antagonizes TGF-β actions and represses renal inflammation, 45, 46 inhibition of its expression could provide a unique mechanism by which Wnt/β-catenin accelerates CKD progression.
THERAPEUTIC STRATEGIES
Given the importance of Wnt/β-catenin signalling in renal fibrogenesis, blockade of this signalling might be beneficial in fibrotic CKD. Indeed, in numerous animal models of CKD, blockade of Wnt/β-catenin at various steps inhibits fibrosis-related gene expression, ameliorates renal fibrosis and improves kidney function. 16 Moreover, because Wnt/β-catenin directly controls the expression of multiple RAS genes, blockade of this signalling, in theory, could simultaneously repress RAS activation and may have superior therapeutic efficacy than anti-RAS remedy, the mainstay of therapy currently used in the clinics for management of CKD patients. Earlier studies indicate that blocking the engagement of Wnt ligands and their receptors by DKK1 or sFRP4 reduces renal fibrotic lesions in animal model of UUO. 17, 32 In addition, blockade of Wnt intracellular signal transduction is also effective in ameliorating renal fibrotic lesions in animal models of CKD. For instance, ICG-001, a small molecule peptidomimetic, can selectively inhibit β-catenin-mediated gene transcription in a cyclic adenosine monophosphate response-element binding protein binding proteindependent fashion. 47 We showed that ICG-001 is able to inhibit the expression of a battery of fibrogenic genes, block tubular EMT, ameliorate renal fibrotic lesions and normalize blood pressure. 33, 43, 48 More importantly, unlike angiotensin-converting enzyme inhibitor or angiotensin receptor blocker that targets one component of the RAS a time, ICG-001 could simultaneously inhibit the expression of multiple components of RAS. 43 This makes it more efficient than anti-RAS therapy in retarding acute kidney injury-CKD progression and ameliorating kidney fibrosis (unpublished data). Klotho is found to physically bind to and functionally sequester Wnt ligands, and therefore acts as an endogenous Wnt antagonist that inhibits Wnt/β-catenin activity. 18 Overexpression of Klotho inhibits the activation of Wnt signalling in UUO and remnant kidney model induced by 5/6 nephrectomy, accompanied by reducing ECM deposition and reducing fibrotic cytokine production. Klotho also attenuates Wnt1-triggered activation of RAS in a dose-dependent manner in renal epithelial cells and normalize blood pressure. 18, 49 These results suggest a novel and mechanistic linkage among Klotho, Wnt/β-catenin and RAS activation in aging and in the pathogenesis of CKD.
CONCLUSION
Over the past several years, significant progress has been made in our understanding of the regulation, receptor complex composition, ligand sources, downstream targets and mechanism of Wnt/β-catenin signalling in the setting of fibrotic CKD. New studies demonstrate that PRR is an endogenous amplifier of Wnt/β-catenin, because it is not only a downstream target but also an obligatory component required for Wnt signal transduction. Although many types of cells in the kidneys may produce and secrete Wnt ligands, selective blockade of Wnt secretion by genetically generating conditional Wls knockout mice suggests that tubular epithelium is the major cellular source of Wnt ligands that play a crucial role in renal fibrogenesis. Furthermore, emerging studies reveal that Wnts can elicit their biological activities not only by inducing the expression of multiple target genes but also through repressing anti-fibrotic HGF expression. In view of that Wnt/β-catenin controls the expression of multiple RAS genes, blocking this signalling may hold its promise to provide a more effective and superior remedy for therapeutic treatment of patients with fibrotic CKD. Undoubtedly, a better understanding of Wnt/β-catenin signalling in the pathogenesis of CKD will eventually translate into new therapeutics in the fight against fibrotic kidney disorders.
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